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The asymmetric synthesis of the antibacterial and antitu-
moral natural compound xylariolide A (1) and five stereoiso-
mers has been achieved. The strategy is based on the one-
pot epoxidation/lactonisation or dihydroxylation/lactonisa-
tion of the hypothetical biosynthetic intermediate xylarioic
Introduction
Trisubstituted γ-butyrolactones are widely distributed in
nature, and they display various biological activities.[1]
Fungi from the Xylaria genus are an abundant source of
natural products from different structural classes, including
terpenoids,[2] cyclopeptides,[3] xanthones,[4] and polyket-
ides.[5] The study of the metabolites produced by an endo-
phytic fungal strain of Xylaria sp. NCY2, isolated from the
medicinal plant Torreya jackii Chun, an evergreen shrub
from the Taxaceae family,[6] led to the isolation of a polyke-
tide γ-lactone named xylariolide A (1; Figure 1). Xylariol-
ide A (1) is structurally related to the tetraketide acid moi-
ety of 1-(xylarenone A) xylariate A (2), another metabolite
isolated from the Xylaria sp. NCY2 strain.
Figure 1. Structures of xylariolide A (1) and 1-(xylarenone A)
xylariate A (2).
Xylariolide A (1) inhibits the growth of the pathogenic
bacteria Escherichia coli, Bacillus subtilis, and Staphylococ-
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A acid (8). The absolute configuration of xylariolide A was
thus determined to be 3R,4S,5R,1R,2R after the synthesis of
1, two epimers, i.e., 1-epi-xylariolide A (3) and 2-epi-xylari-
olide A (4), and three more diastereoisomers 5–7.
cus aureus, and shows moderate antitumoral activity against
HepG2 and HeLa cells.[6] Spectroscopic analysis of isolated
1 led to the proposal that the relative stereochemistry of
compound 1 was 3R*,4S*,5R*, on the basis of nOe corre-
lations; no stereochemical assignments for carbons C-1
and C-2 were established in the original report.
As a part of an ongoing program of research into the
chemical biology of fungal polyketides, including structural
elucidation, biosynthetic, and synthetic studies,[7] our
attention has been drawn to tetraketides such as
xylariolide A (1). The stereoselective preparation of
compound 1 would allow the determination of its
absolute stereochemistry, and would provide material for its
biological evaluation. In this paper, we report the
first stereoselective total synthesis of xylariolide A (1) and
related stereoisomers (3R,4S,5R,1S,2R)-3 (1-epi-xyl-
ariolide A), (3R,4S,5R,1R,2S)-4 (2-epi-xylariolide A),
(3R,4S,5R,1S,2S)-5, (3R,4S,5S,1R,2S)-6, and
(3R,4S,5S,1R,2R)-7. We also report the stereoselective
preparation of xylarioic acid A (8), i.e., the acid moiety of
compound 2, and the assignment of the absolute stereo-
chemistry of compound 1 as 3R,4S,5R,1R,2R.
Results and Discussion
The occurrence of xylarioic A acid (8) as a substructure
of compound 2 suggests that 8 is a biosynthetic precursor
of xylariolides A, B, and C. Based on this, we proposed a
metabolite-inspired retrosynthetic analysis for a stereoselec-
tive synthesis of xylariolide A (1), as shown in Scheme 1.
According to the data from the original report where the
relative stereochemistry for the γ-lactone substituents was
described, a total of eight possible stereoisomers of xylariol-
ide A (1) have to be considered (Figure 2). Therefore, a syn-
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thetic plan should consider the synthesis of diastereomers
arising from all four possible configurations at the 1 and
2 positions. The stereochemistry at the other chiral centres
should be either 3R,4S,5R or 3S,4R,5S, consistent with the
assignment of the relative configuration of the natural prod-
uct in which a cis relationship between the C-3 methyl, the
C-5 methyl, and the C-4 hydroxy groups was determined by
an nOe experiment.[6]
Scheme 1. Retrosynthetic analysis for the synthesis of xylariolide
A.
Figure 2. Stereochemical possibilities for xylariolide A (1).
Our strategy involved the stereoselective synthesis of in-
termediate 8 by the one-pot oxidation/olefination of 2-
methylbutan-1-ol, followed by an anti asymmetric aldol re-
action using an oxazolidinone chiral auxiliary. Starting
from either racemic 2-methylbutan-1-ol or from (2S)-2-
methylbutan-1-ol, the two epimers of (3R,4S,5R,1R)-
xylariolide at C-2 were obtained following the stereoselec-
tive synthetic route proposed in Scheme 2.
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Scheme 2. Stereoselective synthesis of lactone 4 (TFA = trifluoro-
acetic acid; TMS = trimethylsilyl).
Enantiomerically pure acid (6S)-8 was prepared follow-
ing the synthetic sequence showed in Scheme 2. Thus, (S)-
2-methylbutan-1-ol was subjected to a one-pot oxidation/
olefination using N-methylmorpholine N-oxide (NMO;
1.0 equiv.) in the presence of tetrapropylammonium per-
ruthenate (TPAP; 0.03 equiv.), in order to suppress the ra-
cemisation of the aldehyde intermediate, to produce
(2E,4S)-ethyl 2,4-dimethylhex-2-enoate [(S)-10] in 67%
yield.[8] Reduction of (S)-10 with DIBAL (diisobutylalumi-
num hydride) gave alcohol (S)-11, whose subsequent oxi-
dation with PCC (pyridinium chlorochromate) produced
the corresponding aldehyde [i.e., (S)-9].[8] This aldehyde was
treated with oxazolidin-2-one (+)-(S)-12 and catalytic
amounts of MgCl2 and NaSbF6[9] to give anti aldol product
(6S)-14 in 38% yield and with 88 % dr.[10] The configura-
tions of C-2 and C-3 in the aldol product (i.e., 14) were
confirmed by comparison of the NMR spectroscopic data
and optical rotation of (6S)-13, obtained by methanolysis
of (6S)-14, with those reported for the product of the
aldol reaction between (S)-12 and 2-methylcinnamaldehyde,
whose stereochemistry was unequivocally established by
Evans et al.[9]
Oxidative hydrolysis[11] of the chiral auxiliary in (6S)-
13 gave (2R,3S,4E,6S)-3-hydroxy-2,4,6-trimethyloct-4-enoic
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acid [(6S)-8], whose structure was confirmed by a combina-
tion of spectrometric and spectroscopic studies, with par-
ticular importance given to 1D and 2D NMR analysis. The
constitution of compound (6S)-8 is the same as that of the
side-chain of 1-(xylarenone A)xylariate A (2). The 1H
NMR spectroscopic data of (6S)-8 were very similar to
those described for the xylarioyl A moiety of compound
2,[6] although some variations were observed in their 13C
NMR spectra, which could be due to stereochemical differ-
ences.
Acid (6S)-8 was subjected to a one-pot stereoselective
epoxidation with m-CPBA (m-chloroperbenzoic acid), and
a lactonisation catalysed by BF3·Et2O[12] to give γ-butyro-
lactone 4. A series of nOe effects between the signals at δH
= 3.07, 4.58, and 3.64 ppm (due to H-3, H-4, and H-1,
respectively; Figure 3), consistent with a cis-cis relative con-
figuration for the methyl and hydroxy groups in the lactone
ring, supported the assignment of the stereochemistry of
compound 4 as 3R,4S,5R,1R,2S.
Figure 3. Selected nOe correlations for compound 4.
This outcome is consistent with the reaction mechanism
outlined in Scheme 3 in which the hydroxy-directed epoxid-
ation of (6S)-8 is predicted to give a threo-epoxide.[13] This
then undergoes an epoxide ring opening by intramolecular
nucleophilic attack of the carboxylic acid fragment with in-
version of configuration at C-4, to give the lactone ring with
a 3R,4S,5R,1R configuration.
Comparison of the spectroscopic data of compound 4
with those reported for xylariolide A showed significant dif-
ferences in both the 1H and the 13C NMR data, especially
in those signals corresponding to the side-chain (see
Tables 1 and 2). With the aim of examining whether these
differences were due to the alternative stereochemistry at C-
Table 2. Comparison of 1H NMR data of 1, 3–5, and xylariolide A.[a]
Proton 1 3 4 5 Xylariolide A[6]
H-3 3.01 (quint, 7.6) 3.11 (quint, 7.2) 3.07 (quint, 7.5) 3.08 (quint, 7.4) 3.03 (quint, 7.4)
C-3-Me 1.25 (d, 7.6) 1.24 (d, 7.2) 1.24 (d, 7.5) 1.25 (d, 7.4) 1.27 (d, 7.5)
H-4 4.55 (dd, 5.0, 7.6) 4.45 (dd, 4.2, 7.2) 4.58 (dd, 4.8, 7.5) 4.41 (d, 7.4) 4.57 (d, 7.4)
C-5-Me 1.38 (s) 1.37 (s) 1.37 (s) 1.38 (s) 1.39 (s)
H-1 3.45 (t, 5.6) 3.55 (dd, 2.2, 7.0) 3.64 (dd, 3.2, 5.6) 3.45 (d, 3.6) 3.46 (d, 5.6)
H-2 1.57–1.63 (m) 1.77 (dsext, 2.2, 7.2) 1.64–1.72 (m) 1.70–1.84 (m) 1.56–1.62 (m)
C-2-Me 1.00 (d, 6.8) 0.95 (d, 7.2) 0.96 (d, 6.8) 1.01 (d, 7.2) 1.02 (d, 6.8)
H-3a 1.19–1.28 (m) 1.29–1.36 (m) 1.28–1.37 (m) 1.05–1.16 (m) 1.19–1.21 (m)
H-3b 1.64–1.71 (m) 1.38–1.44 (m) 1.40–1.49 (m) 1.70–1.84 (m) 1.56–1.62 (m)
H-4 0.92 (t, 7.6) 0.92 (t, 7.2) 0.91 (t, 7.2) 0.91 (t, 7.2) 0.94 (t, 7.4)
C-4-OH 1.79 (d, 5.0) 1.71 (d, 4.2) 1.72 (d, 4.8) – –
C-1-OH 1.86 (d, 5.6) 1.64 (d, 7.0) 1.84 (d, 5.6) – –
[a] Chemical shift values, δ, are in ppm, and coupling constants, J, are in Hz (in parentheses).
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Scheme 3. Stereoselective epoxidation of acid (6S)-8 gave lactone
4.
1, we prepared diastereoisomers of compound 4, with the
same absolute stereochemistry at C-3, C-4, and C-5. Dihy-
droxylation of acid (6S)-8 catalysed by OsO4[14] gave a 1:1
mixture of the two triols resulting from syn-dihydroxylation
on each of the faces of the olefin, and this was followed by
in situ lactonisation to give lactones 5 and 6 (Scheme 4).
Table 1. Comparison of 13C NMR data of 1, 3–5, and xylariolide
A.[a]
Carbon 1 3 4 5 Xylariolide A[6]
C-2 178.4 178.7 178.7 178.4 178.6
C-3 40.2 40.2 40.8 40.1 40.2
C-4 9.3 9.3 9.2 9.2 9.3
C-5 72.4 73.8 71.5 73.7 72.7
C-1 90.4 90.6 91.3 90.7 90.3
C-2 16.6 17.0 17.5 16.6 16.6
C-3 79.7 77.4 78.0 79.4 79.8
C-4 36.5 35.7 35.9 36.2 36.6
C-3-Me 16.9 13.0 13.5 17.5 16.9
C-5-Me 24.1 28.3 28.1 22.8 24.1
C-1-Me 11.2 11.9 11.6 11.7 11.2
[a] Chemical shift values, δ, are in ppm.
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Scheme 4. Synthesis of lactones 5 and 6.
NOe correlations between protons H-3, H-4, and H-1 in
compound 5 were consistent with the relative configuration
of the γ-butyrolactone moiety present in xylariolide A (1),
but its observed physical and spectroscopic data turned out
to be different from those reported for the natural product
(see Tables 1 and 2). At this point, it seemed clear that natu-
ral xylariolide A or its enantiomer should have an alterna-
tive 2R configuration. Therefore, our aim was to obtain
the diastereomer of compound 4 that was epimeric at this
position, which could be prepared stereoselectively follow-
ing an identical synthetic sequence, starting from (R)-2-
methylbutan-1-ol.[15,16]
Commercially available ()-2-methylbutan-1-ol was sub-
jected to one-pot oxidation/olefination using the TEMPO–
BAIB [2,2,6,6-tetramethylpiperidin-1-oxyl and bis(acetoxy)-
iodobenzene] system and (carbethoxyethylidene)triphenyl-
phosphorane[17] to give ()-(E)-ethyl 2,4-dimethylhex-2-en-
oate [()-10] in 61% yield.[18] Reduction of ()-10 with
DIBAL and subsequent oxidation with PCC produced the
corresponding aldehyde [i.e., ()-9].[8] This aldehyde was
treated with oxazolidin-2-one [(+)-12] and catalytic
amounts of MgCl2 and NaSbF6[9] to give a 1:1 mixture of
anti aldols (6R)-13 and (6S)-13 after methanolysis of the
silyloxy derivatives (6R)-14 and (6S)-14 (Scheme 5). The
mixture of (6R)-13 and (6S)-13 was subjected to oxidat-
ive hydrolysis[11] to give a 1:1 mixture of (2R,3S,4E,6R)-
and (2R,3S,4E,6S)-3-hydroxy-2,4,6-trimethyloct-4-enoic
acids, i.e., (6R)-8 and (6S)-8.
The 1:1 mixture of (6S)-8 and (6R)-8 was subjected to a
one-pot stereoselective epoxidation with m-CPBA, and sub-
sequent lactonisation catalysed by BF3·Et2O[12] to give a 1:1
mixture of compounds 1 and 4, which were then separated
by chromatographic methods. NOe’s observed between the
signals at δH = 3.01, 4.55, and 3.45 ppm (H-3, H-4, and H-
1, respectively) supported the assignment of the stereo-
chemistry for compound 1 as 3R,4S,5R,1R,2R.
The 13C NMR chemical shifts of lactone 1 were identical
to those reported for xylariolide A (Table 1). However, there
were slight differences in the signals corresponding to H-2
and H-3 in the 1H NMR spectra (Table 2).
With the aim of ruling out the possibility that these dif-
ferences were due to an alternative stereochemistry at C-1,
acids (6S)-8 and (6R)-8 were subjected to dihydroxylation
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Scheme 5. Synthesis of lactones 1 and 4.
catalysed by OsO4[14] to give a 1:1:1:1 mixture of four triols
resulting from syn-dihydroxylation on both faces of the ole-
fin on each diastereomer, which, after in situ lactonisation,
led to the corresponding lactones (i.e., 3 and 5–7;
Scheme 6). Lactone 3 showed nOe’s consistent with those
described for xylariolide A, but again its physical and spec-
troscopic data turned out to be different from those re-
ported for the natural product (see Tables 1 and 2).
Scheme 6. Synthesis of lactones 3 and 5–7.
All this data indicated that natural xylariolide A had a
relative stereochemistry identical to that of compound 1,
and that the slight differences observed between their 1H
NMR spectra could be due to errors in the definition of the
intervals in the original report.
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Finally, the optical rotation of compound 1 [+5.3 (c =
0.66, CHCl3)] was of the same sign and magnitude as the
value originally described for xylariolide A ([α]D20 = +7.55,
c = 0.54, CHCl3).[6]
Conclusions
We have synthesised four possible diastereoisomers of
4-hydroxy-5-(1-hydroxy-2-methylbutyl)-3,5-dimethyl-4,5-di-
hydrofuran-2(3H)-one in which the configuration of the
lactone ring was consistent with the stereochemical descrip-
tion made in the original report by Hu et al. for xylariolide
A.[6] Only compound 1 showed spectroscopic and physical
data consistent with those reported for the natural com-
pound. The slight differences in the 1H NMR data between
the isolated and synthetic material could be due to errors
in the definition of the intervals in the original report (see
Tables 1 and 2). Compound 1 was synthesised stereoselec-
tively from (R)-2-methylbutan-1-ol, whose preparation has
been reported previously in the literature.[16]
Experimental Section
General Methods: Unless otherwise noted, materials and reagents
were obtained from commercial suppliers, and were used without
further purification. Dichloromethane, ethyl acetate and triethyl-
amine were freshly distilled from CaH2. Air- and moisture-sensitive
reactions were performed under an argon atmosphere. Purification
by semi-preparative and analytical HPLC was performed with a
Hitachi/Merck L-6270 apparatus equipped with a differential re-
fractometer detector (RI-7490). A LiChrospher® Si 60 (5 μm)
LiChroCart® (250 mm 4 mm) column and a LiChrospher® Si 60
(10 μm) LiChroCart® (250 mm10 mm) were used in isolation ex-
periments. Silica gel (Merck) was used for column chromatography.
TLC was performed on Merck Kiesegel 60 F254, 0.25 mm thick
plates. Melting points were measured with a Reichert–Jung Kofler
block. Optical rotations were determined with a digital polarimeter.
Infrared spectra were recorded with a FTIR spectrophotometer
and are reported in wavenumbers (cm –1). 1H and 13C NMR mea-
surements were recorded with Varian Unity 400 MHz, Agilent
500 MHz, and Varian Inova 600 MHz spectrometers with SiMe4
as the internal reference. Chemical shifts were referenced to CDCl3
(δH = 7.25, δC = 77.0). NMR assignments were made using a com-
bination of 1D and 2D techniques. Multiplicities are described
using the following abbreviations: s = singlet, d = doublet, t =
triplet, q = quartet; quint = quintuplet; sext = sextuplet; m = mul-
tiplet, br = broad. High-resolution mass spectra (HRMS) were re-
corded with a double-focussing magnetic sector mass spectrometer
in positive ion mode, or with a QTOF mass spectrometer in positive
ion APCI mode.
(2E,4S)-Ethyl 2,4-Dimethylhex-2-enoate [(S)-10]: A mixture of (S)-
2-methylbutan-1-ol (600 mg, 6.82 mmol), 4-methylmorpholine N-
oxide (NMO; 865 mg, 7.16 mmol) and molecular sieves (4 Å beads;
1.4 g) in dry CH2Cl2 (13.6 mL) was stirred for 15 min. TPAP
(126 mg, 0.2 mmol) was added to the resulting mixture. After stir-
ring for 6 h at room temperature, (ethoxycarbonylethylidene)tri-
phenylphosphorane was added, and the solution was stirred for a
further 12 h at 35 °C (3.9 g, 10.2 mmol). The mixture was then
warmed to room temperature, the solvent was removed under re-
duced pressure, and the residue was purified by silica gel column
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chromatography (petroleum ether/Et2O, 97:3) to give ester (S)-10
(776.6 mg, 67%). The spectroscopic data for compound (S)-10 were
identical to those described in the literature.[8]
()-(E)-Ethyl 2,4-Dimethylhex-2-enoate [()-10]: TEMPO (561 mg,
3.50 mmol) and [bis(acetoxyiodo)benzene] (BAIB; 12.4 g,
38.70 mmol) were added at 0 °C to a solution of (S)-2-methylbu-
tan-1-ol (1550 mg, 17.60 mmol) in dry CH2Cl2 (38.7 mL), and the
mixture was stirred for 6 h. Then, (ethoxycarbonylethylidene)tri-
phenylphosphorane (16.3 g, 44.02 mmol) was added, and the solu-
tion was stirred for a further 12 h at 35 °C. The mixture was
warmed to room temperature, the solvent was removed under re-
duced pressure, and the residue was purified by silica gel column
chromatography (petroleum ether/Et2O, 97:3) to give ester ()-10
(1826.3 mg, 61%). The spectroscopic data for compound ()-10
were identical to those described in the literature.[18]
(2E,4S)-2,4-Dimethylhex-2-en-1-ol [(S)-11]: Diisobutylaluminum
hydride (DIBAL; 1.0 m in CH2Cl2; 4.3 mL, 4.3 mmol) was slowly
added to a solution of (2E,4S)-ethyl 2,4-dimethylhex-2-enoate [(S)-
10] (726 mg, 4.27 mmol) in dry CH2Cl2 (13.4 mL), and the mixture
was cooled to –78 °C. When TLC monitoring indicated that the
reaction was complete, Rochelle’s salt (saturated aq.; 25 mL) was
added, and the mixture was warmed to room temperature while
maintaining vigorous stirring. The aqueous phase was extracted
with CH2Cl2 (3 40 mL), and the combined organic extracts were
washed, dried with anhydrous sodium sulfate and filtered. Evapo-
ration of the solvent gave a crude residue, which was purified by
silica gel column chromatography (petroleum ether/EtOAc, 80:20)
to give (2E,4S)-2,4-dimethylhex-2-en-1-ol [(S)-11] (400.2 mg, 73%),
whose spectroscopic data were identical to those described in the
literature.[18]
()-2,4-Dimethylhex-2-en-1-ol [()-11]: ()-(E)-Ethyl 2,4-dimeth-
ylhex-2-enoate [()-10] (1400 mg, 8.24 mmol) was converted into
()-2,4-dimethylhex-2-en-1-ol [()-11] (896.5 mg, 85%) following
the method described above for the synthesis of (2E,4S)-2,4-di-
methylhex-2-en-1-ol [(S)-11] from (S)-10.
(2E,4S)-2,4-Dimethylhex-2-enal [(S)-9]: (2E,4S)-2,4-Dimethylhex-2-
en-1-ol [(S)-11] (400.2 mg, 3.13 mmol) was dissolved in CH2Cl2
(5 mL), and the solution was added dropwise to a suspension of
PCC (1.031 g, 4.71 mmol) and powdered molecular sieves (4 Å,
2.062 g) in CH2Cl2 (15 mL) at 0 °C. The reaction mixture was
stirred vigorously at 0 °C for 2 h, then diethyl ether (50 mL) was
added, and the mixture was stirred for an additional 1 h. The sus-
pension was filtered through a silica gel pad (pentane/Et2O, 80:20,
300 mL). The solvent was concentrated under reduced pressure at
0 °C to give aldehyde (S)-9 (364.0 mg, 92%), which was used imme-
diately in the next step. The spectroscopic data for compound (S)-
9 were identical to those described in the literature.[8]
()-2,4-Dimethylhex-2-enal [()-9]: ()-2,4-Dimethylhex-2-en-1-ol
[()-11] (400.5 mg, 3.12 mmol) was converted into ()-2,4-dimeth-
ylhex-2-enal [()-9] (354.4 mg, 90%) following the method de-




Benzyl-3-propionyloxazolidin-2-one [(+)-(S)-12 ] (509 mg,
2.18 mmol) was treated with MgCl2 (20.8 mg, 0.22 mmol), NaSbF6
(169.2 mg, 0.65 mmol), triethylamine (0.52 mL, 4.4 mL), aldehyde
(S)-9 (330.0 mg, 2.62 mmol), and chlorotrimethylsilane (0.37 mL,
3.3 mmol) in ethyl acetate (5.4 mL) at 25 °C for 48 h. The resulting
orange slurry was passed through a pad of silica, eluting with Et2O
(200 mL). The solvent was removed under reduced pressure, and
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the residue was purified by silica gel column chromatography (pe-
troleum ether/Et2O, 94:6) to give (6S)-14 (357.7 mg, 38%) with
88% dr as a colourless oil. The mixture was separated by analytical
HPLC [hexane/ethyl acetate (92:8), flow: 0.8 mL/min; tR = 14 min
for minor isomer and tR = 21 min for (6S)-14]. Data for (6S)-
14: [α]D20 = +35.9 (c = 2.1, CHCl3). IR (film): ν̃ = 2960, 2874, 1783,
1700, 1455, 1387, 1250, 1055, 882, 841 cm–1. 1H NMR (400 MHz,
CDCl3): δ = 7.33 (m, 2 H), 7.28–7.24 (m, 3 H), 5.16 (d, J = 9.2 Hz,
1 H), 4.71 (m, 1 H), 4.29 (d, J = 10.0 Hz, 1 H), 4.18–4.08 (m, 3
H), 3.33 (dd, J = 13.2, 3.2 Hz, 1 H), 2.70 (dd, J = 13.2, 9.6 Hz, 1
H), 2.31 (m, 1 H), 1.62 (d, J = 0.8 Hz, 3 H), 1.40–1.31 (m, 1 H),
1.27–1.15 (m, 1 H), 0.97–0.94 (m, 6 H), 0.83 (t, J = 7.6 Hz, 3 H),
0.04 (s, 9 H) ppm. 13C NMR (100 MHz, CDCl3): δ = 176.6, 153.2,
136.4, 135.6, 133.4, 129.5, 129.0, 127.2, 82.5, 65.6, 55.1, 41.4, 38.1,
34.0, 30.2, 20.2, 14.4, 12.1, 10.5, 0.2 ppm. HRMS (APCI+): calcd.
for C21H28NO3 [M + H – (CH3)3SiOH]+ 342.2069; found 342.2087.
Data for the minor isomer: Colourless oil. [α]D20 = +11.2 (c = 0.1,
CHCl3). IR (film): ν̃ = 2960, 2837, 1783, 1705, 1445, 1250, 1055,
887 cm–1. 1H NMR (500 MHz, CDCl3): δ = 7.33 (m, 2 H), 7.28–
7.20 (m, 3 H), 5.14 (d, J = 9.8 Hz, 1 H), 4.66 (m, 1 H), 4.34 (d, J
= 9.6 Hz, 1 H), 4.16–4.08 (m, 3 H), 3.26 (dd, J = 13.2, 3.3 Hz, 1
H), 2.80 (dd, J = 13.2, 9.6 Hz, 1 H), 2.29 (m, 1 H), 1.58 (s, 3 H),
1.40–1.22 (m, 2 H), 0.97 (d, J = 6.0 Hz, 3 H), 0.92 (d, J = 6.7 Hz,
3 H), 0.86 (t, J = 7.4 Hz, 3 H), 0.01 (s, 9 H) ppm. 13C NMR
(125 MHz, CDCl3): δ = 176.5, 153.4, 136.3, 135.5, 133.3, 129.5,
128.9, 127.2, 82.8, 65.8, 55.5, 41.0, 38.2, 33.9, 30.0, 20.6, 13.9, 12.1,
10.4, 0.0 ppm. HRMS (APCI+): calcd. for C21H28NO3 [M + H –
(CH3)3SiOH]+ 342.2069; found 342.2070.
(4S,2R,3S,4E,6S)-4-Benzyl-3-[3-hydroxy-2,4,6-trimethyloct-
4-enoyl]oxazolidin-2-one [(6S)-13]: Trifluoroacetic acid (0.15 mL,
1.78 mmol) was added to a stirred solution of (6S)-14 (357.7 mg,
0.83 mmol) in dry methanol (30 mL) at 0 °C, and the mixture was
stirred for 15 min. Evaporation of the solvent gave a crude residue,
which was purified by silica gel column chromatography (petroleum
ether/EtOAc, 90:10) to give (6S)-13 (282.7 mg, 95%) as a colour-
less oil. [α]D20 = +61.8 (c = 1.6, CHCl3). IR (film): ν̃ = 3504, 2960,
2874, 1781, 1691, 1458, 1389, 1210, 1016, 968, 707 cm–1. 1H NMR
(400 MHz, CDCl3): δ = 7.35–7.30 (tt, J = 7.2, 1.6 Hz, 2 H),
7.27.7.22 (m, 3 H), 5.22 (dd, J = 9.6, 1.0 Hz, 1 H), 4.69 (m, 1 H),
4.20–4.06 (m, 4 H), 3.31 (dd, J = 13.6, 3.2 Hz, 1 H), 2.78 (dd, J =
13.6, 9.6 Hz, 1 H), 2.30 (m, 1 H), 1.67 (d, J = 1.0 Hz, 3 H), 1.35
(m, 1 H), 1.22 (m, 1 H), 1.04 (d, J = 6.4 Hz, 3 H), 0.94 (d, J =
6.8 Hz, 3 H), 0.83 (t, J = 7.4 Hz, 3 H) ppm. 13C NMR (100 MHz,
CDCl3): δ = 176.8, 153.9, 136.6, 135.3, 132.9, 129.5, 128.9, 127.3,
81.8, 66.0, 55.7, 40.6, 37.8, 33.9, 30.2, 20.5, 14.8, 12.0, 10.8 ppm.




[()-9] (550 mg, 4.36 mmol) was converted into an inseparable 1:1
mixture of (4S,2R,3S,4E,6R)-4-benzyl-3-[3-hydroxy-2,4,6-tri-
m e t hy l o c t - 4 - e n oy l ] ox a z o l i d i n - 2 - o n e [ ( 6   R ) - 1 3 ] a n d
(4S,2R,3S,4E,6S)-4-benzyl-3-[3-hydroxy-2,4,6-trimethyloct-
4-enoyl]oxazolidin-2-one [(6S)-13] (547.8 mg, 35 %; 88% dr) fol-
lowing the method described above for the synthesis of (6S)-13
from (S)-9.
(2R,3S,4E,6S)-3-Hydroxy-2,4,6-trimethyloct-4-enoic Acid [(6S)-8]:
H2O2 (30 %; 0.12 mL, 1.12 mmol) and LiOH·H2O (26.0 mg,
0.56 mmol) were added to a stirred solution of (6S)-13 (100 mg,
0.28 mmol) in THF/H2O (4:1; 1.8 mL) at 0 °C. The mixture was
then warmed to room temperature and stirred for 2 h. Sodium sulf-
ite (1 m aq.; 1.12 mL, 1.12 mmol) was then added, and the mixture
Eur. J. Org. Chem. 2013, 2420–2427 © 2013 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.eurjoc.org 2425
was stirred for an additional 20 min. The organic solvent was re-
moved under reduced pressure, and the aqueous phase was ex-
tracted with CH2Cl2 (3 4 mL). The aqueous phase was acidified
with HCl (1 m) to pH = 2 and then extracted with ethyl acetate (3
15 mL). The combined organic extracts were dried with anhydrous
sodium sulfate and filtered, and the solvent was evaporated under
reduced pressure to give acid (6S)-8 (52.4 mg, 94%) as a colourless
oil, which was used in the next step without further purification.
[α]D20 = +37.3 (c = 0.6, CHCl3). IR (film): ν̃ = 3418, 2961, 2874,
1715, 1456, 1379, 1200, 1004, 876 cm–1. 1H NMR (400 MHz,
CDCl3): δ = 5.19 (d, J = 9.2 Hz, 1 H), 4.09 (d, J = 8.8 Hz, 1 H),
2.64 (dq, J = 8.8, 6.8 Hz, 1 H), 2.28 (m, 1 H), 1.59 (s, 3 H), 1.37–
1.29 (m, 1 H), 1.25–1.16 (m, 1 H), 1.03 (d, J = 6.8 Hz, 3 H), 0.93
(d, J = 6.8 Hz, 3 H), 0.81 (t, J = 7.4 Hz, 3 H) ppm. 13C NMR
(100 MHz, CDCl3): δ = 180.6, 137.1, 132.2, 80.4, 43.1, 33.9, 30.1,
20.5, 14.2, 12.0, 10.5 ppm. HRMS (CI+): calcd. for C11H20O3
[M]+ 200.1412; found 200.1410.
(2R,3S,4E,6R)-3-Hydroxy-2,4,6-trimethyloct-4-enoic Acid [(6R)-8]:
A 1:1 mixture of (6R)-13 and (6S)-13 (102 mg, 0.28 mmol) was
converted into an inseparable 1:1 mixture of epimeric acids (6R)-8
and (6S)-8 (52.6 mg, 94%) following the method described above
for the synthesis of (6S)-8 from (6S)-13.
(3R,4S,5R,1R,2S)-4-Hydroxy-5-(1-hydroxy-2-methylbutyl)-3,5-
dimethyl-4,5-dihydrofuran-2(3H)-one (4): m-Chloroperbenzoic acid
(36.7 mg, 0.17 mmol) was added to a stirred solution of acid (6S)-
8 (29.8 mg, 0.15 mmol) in dry CH2Cl2 (1 mL). After stirring for
2 h, the mixture was cooled to 0 °C, and BF3·Et2O (0.2 m in
CH2Cl2; 0.15 mL, 0.03 mmol) was added. The mixture was then
warmed to room temperature and stirred for a further 1 h. The
solvent was removed under reduced pressure, and ethyl acetate
(5 mL) was added. The organic phase was washed with sodium
hydrogen carbonate (saturated aq.; 3 3 mL), dried with anhy-
drous sodium sulfate, filtered, and concentrated under reduced
pressure. The crude residue was purified by silica gel column (pe-
troleum ether/EtOAc, 80:20) to give lactone 4 (17.0 mg, 53%) as a
white solid, m.p. 109–111 °C. [α]D20 = +2.4 (c = 0.7, CHCl3). IR
(film): ν̃ = 3416, 2968, 2882, 1751, 1452, 1381, 1233, 1168, 1053,
990 cm–1. 1H NMR (600 MHz, CDCl3): δ = 4.58 (dd, J = 7.5,
4.8 Hz, 1 H), 3.64 (dd, J = 5.6, 3.2 Hz, 1 H), 3.07 (quint, J =
7.5 Hz, 1 H), 1.84 (d, J = 5.6 Hz, C-1-OH), 1.72 (d, J = 4.8 Hz,
C-4-OH), 1.72–1.64 (m, 1 H), 1.49–1.40 (m, 1 H), 1.37 (s, 3 H),
1.37–1.28 (m, 1 H), 1.24 (d, J = 7.5 Hz, 3 H), 0.96 (d, J = 6.8 Hz,
3 H), 0.91 (t, J = 7.2 Hz, 3 H) ppm. 13C NMR (150 MHz, CDCl3):
δ = 178.7, 91.3, 78.0, 71.5, 40.8, 35.9, 28.1, 17.5, 13.5, 11.6,
9.2 ppm. HRMS (CI): calcd. for C11H21O4 [M + H]+ 217.1440;
found 217.1432.
(3R,4S,5R,1R,2R)-4-Hydroxy-5-(1-hydroxy-2-methylbutyl)-3,5-
dimethyl-4,5-dihydrofuran-2(3H)-one (1): An inseparable 1:1 mix-
ture of epimeric acids (S)-8 and (R)-8 (35.2 mg, 0.18 mmol) was
converted into a mixture of lactones 1 and 4 (20.2 mg, 52%) follow-
ing the method described above for the synthesis of lactone 4 from
acid (S)-8. The reaction mixture was purified by silica gel column
chromatography (petroleum ether/EtOAc, 80:20) to give a mixture
of lactones 1 and 4, which was further purified by semi-preparative
HPLC [Hexane/ethyl acetate (63:37), flow: 3.0 mL/min; tR = 25 min
for lactone 1 and tR = 20 min for lactone 4]. Data for 1: Colourless
oil. [α]D20 = +5.3 (c = 0.66, CHCl3). IR (film): ν̃ = 3433, 2926, 1751,
1458, 1380, 1224, 1168, 1036, 992 cm–1. 1H NMR (600 MHz,
CDCl3): δ = 4.55 (dd, J = 5.0, 7.6 Hz, 1 H), 3.45 (t, J = 5.6 Hz, 1
H), 3.01 (quint, J = 7.6 Hz, 1 H), 1.86 (d, J = 5.6 Hz, C-1-OH),
1.79 (d, J = 5.0 Hz, C-4-OH), 1.71–1.64 (m, 1 H), 1.63–1.57 (m, 1
H), 1.38 (s, 3 H), 1.28–1.19 (m, 1 H), 1.25 (d, J = 7.6 Hz, 3 H),
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1.00 (d, J = 6.8 Hz, 3 H), 0.92 (t, J = 7.6 Hz, 3 H) ppm. 13C NMR
(150 MHz, CDCl3): δ = 178.4, 90.4, 79.7, 72.4, 40.2, 36.5, 24.1,
16.9, 16.6, 11.2, 9.3 ppm. HRMS (CI+): calcd. for C11H21O4 [M +
H]+ 217.1440; found 217.1436.
Dihydroxylation/Lactonisation of Acid (S)-8: Trimethylamine N-ox-
ide (13.4 mg, 0.10 mmol), pyridine (25 μL, 0.17 mmol), and water
(0.2 mL) were added to a 1:1 solution of acids (S)-8 and (R)-8
(16.8 mg, 0.08 mmol) in tBuOH (0.2 mL), and the mixture was
stirred at 25 °C. OsO4 (2.5 % w/w solution in tBuOH; 63 μL,
0.025 mmol) was added dropwise, and the reaction mixture was
stirred for 18 h at room temperature. Sodium bisulfite (20% aq. w/
v; 2 mL) was then added, and the mixture was stirred for a further
1 h. Most of the tBuOH was removed under reduced pressure, and
the residue was then extracted into EtOAc (3  5 mL). The com-
bined organic extracts were washed with brine (10 mL), dried with
anhydrous sodium sulfate, and filtered, and the solvent was evapo-
rated under reduced pressure. Purification by silica gel column
chromatography (petroleum ether/EtOAc, 60:40) and analytical
HPLC [hexane/ethyl acetate (65:35); flow: 0.8 mL/min] gave a 1:1
mixture of epimeric acids 5 and 6 (12.5 mg, 69%).
(3R,4S,5R,1S,2S)-4-Hydroxy-5-(1-hydroxy-2-methylbutyl)-3,5-
dimethyl-4,5-dihydrofuran-2(3H)-one (5): Colourless oil; tR =
43 min. [α]D20 = –2.4 (c = 0.1, CHCl3). IR (film): ν̃ = 3430, 2964,
2939, 1748, 1461, 1380, 1232, 1170, 1064, 991 cm–1. 1H NMR
(400 MHz, CDCl3): δ = 4.41 (d, J = 7.4 Hz, 1 H), 3.45 (d, J =
3.6 Hz, 1 H), 3.08 (quint, J = 7.4 Hz, 1 H), 1.84–1.70 (m, 2 H),
1.38 (s, 3 H), 1.25 (d, J = 7.4 Hz, 3 H), 1.16–1.05 (m, 1 H), 1.01
(d, J = 7.2 Hz, 3 H), 0.91 (t, J = 7.2 Hz, 3 H) ppm. 13C NMR
(100 MHz, CDCl3): δ = 178.4, 90.7, 79.4, 73.7, 40.1, 36.2, 22.8,
17.5, 16.6, 11.7, 9.2 ppm. HRMS (CI+): calcd. for C11H21O4 [M +
H]+ 217.1440; found 217.1433.
(3R,4S,5S,1R,2S)-4-Hydroxy-5-(1-hydroxy-2-methylbutyl)-3,5-
dimethyl-4,5-dihydrofuran-2(3H)-one (6): Colourless oil; tR =
18 min. [α]D20 = +10.6 (c = 0.16, CHCl3). IR (film): ν̃ = 3434, 2964,
2878, 1760, 1456, 1222, 1062, 940 cm–1. 1H NMR (400 MHz,
CDCl3): δ = 4.30 (d, J = 6.0 Hz, C-4-OH), 4.15 (t, J = 6.0 Hz, 1
H), 4.03 (d, J = 7.2 Hz, 1 H), 2.85 (dq, J = 7.0, 6.0 Hz, 1 H), 2.26
(d, J = 9.6 Hz, C-1-OH), 1.75 (dsext, J = 7.2, 2.2 Hz, 1 H), 1.54–
1.44 (m, 1 H), 1.43–1.33 (m, 1 H), 1.31 (s, 3 H), 1.26 (d, J = 7.0 Hz,
3 H), 0.96 (d, J = 7.2 Hz, 3 H), 0.95 (t, J = 7.6 Hz, 3 H) ppm. 13C
NMR (100 MHz, CDCl3): δ = 178.5, 87.0, 78.5, 75.0, 39.7, 35.6,
27.5, 21.3, 12.8, 12.0, 8.3 ppm. HRMS (CI+): calcd. for C11H21O4
[M + H]+ 217.1440; found 217.1443.
Dihydroxylation/Lactonisation of Acids (S)-8 and (R)-8: A 1:1 mix-
ture of (S)-8 and (R)-8 (20 mg, 0.1 mmol) was converted into lac-
tones 3 (2.9 mg, 13%), 5 (2.9 mg, 13%), 6 (2.9 mg, 13%), and 7
(2.9 mg, 13%), following the method described above for the dihy-
droxylation/lactonisation of (S)-6. Purification by silica gel column
chromatography (petroleum ether/EtOAc, 60:40) and analytical
HPLC [Hexane/ethyl acetate (65:35); flow: 0.8 mL/min] gave a
1:1:1:1 mixture of epimeric acids 3, 5, 6, and 7.
(3R,4S,5R,1S,2R)-4-Hydroxy-5-(1-hydroxy-2-methylbutyl)-3,5-
dimethyl-4,5-dihydrofuran-2(3H)-one (3): Colourless oil; tR =
40 min. [α]D20 = +8.0 (c = 0.11, CHCl3). IR (film): ν̃ = 3434, 2964,
2878, 1747, 1460, 1380, 1238, 1177, 1062, 991 cm–1. 1H NMR
(500 MHz, CDCl3): δ = 4.45 (dd, J = 7.2, 4.2 Hz, 1 H), 3.55 (dd,
J = 7.0, 2.2 Hz, 1 H), 3.11 (quint, J = 7.2 Hz, 1 H), 1.77 (dsext, J
= 7.2, 2.2 Hz, 1 H), 1.71 (d, J = 4.2 Hz, C-4-OH), 1.64 (d, J =
7.0 Hz, C-1-OH), 1.44–1.38 (m, 1 H), 1.37 (s, 3 H), 1.36–1.29 (m,
1 H), 1.24 (d, J = 7.2 Hz, 3 H), 0.95 (d, J = 7.2 Hz, 3 H), 0.92 (t,
J = 7.2 Hz, 3 H) ppm. 13C NMR (125 MHz, CDCl3): δ = 178.7,
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90.6, 77.4, 73.8, 40.2, 35.7, 28.3, 17.0, 13.0, 11.9, 9.3 ppm. HRMS
(CI+): calcd. for C11H21O4 [M + H]+ 217.1440; found 217.1442.
(3R,4S,5S,1R,2R)-4-Hydroxy-5-(1-hydroxy-2-methylbutyl)-3,5-
dimethyl-4,5-dihydrofuran-2(3H)-one (7): Colourless oil; tR =
16 min. [α]D20 = +1.9 (c = 0.10, CHCl3). IR (film): ν̃ = 3434, 2964,
2878, 1759, 1456, 1226, 1062, 940 cm–1. 1H NMR (400 MHz,
CDCl3): δ = 4.15 (d, J = 6.8 Hz, 1 H), 3.93 (d, J = 3.6 Hz, 1 H),
2.87 (quint, J = 6.8 Hz, 1 H), 1.82–1.72 (m, 2 H), 1.43–1.33 (m, 1
H), 1.32 (s, 3 H), 1.26 (d, J = 6.8 Hz, 3 H), 1.06 (d, J = 6.8 Hz, 3
H), 0.93 (t, J = 7.6 Hz, 3 H) ppm. 13C NMR (100 MHz, CDCl3):
δ = 178.1, 87.3, 78.2, 77.2, 39.9, 35.9, 22.2, 20.8, 16.6, 11.8,
8.3 ppm. HRMS (CI+): calcd. for C11H21O4 [M + H]+ 217.1440;
found 217.1438.
Supporting Information (see footnote on the first page of this arti-
cle): Copies of the 1H and 13C NMR spectra for all key intermedi-
ates and final products, and nOe spectra of 1 and 3–7.
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